Asundexian approval, endometrial cancer priority review and osteosarcoma research.
China’s medicines regulator approved asundexian following priority review. In a 12,327-patient late-stage trial, recurrent ischaemic stroke occurred in 6.2% of patients receiving asundexian versus 8.4% with placebo; Chinese launch timing and pricing were not disclosed.
Why it matters: Marks a significant regulatory development in stroke prevention and a major pharmaceutical market.
Read at Reuters →Investigational sacituzumab tirumotecan extended median overall survival to 19 months versus 12.1 months with chemotherapy in a 776-patient trial. Severe treatment-related adverse effects were more frequent, at approximately 54% versus 41%; an FDA decision is expected by June 2027.
Why it matters: Adds late-stage evidence for a potential treatment in previously treated advanced endometrial cancer, with benefit and toxicity both requiring assessment.
Read at Reuters →Experimental ris-rez extended median progression-free survival to 5.5 months versus 1.4 months with chemotherapy in a Chinese late-stage trial. The study enrolled 122 patients aged 12 and older with heavily pretreated osteosarcoma; these findings do not establish an overall-survival benefit or regulatory approval.
Why it matters: Provides encouraging evidence in a difficult-to-treat bone cancer, warranting further evaluation of safety, durability and applicability beyond the study population.
Read at Reuters →Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.